Drugs / RFUS-949
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07676357 | Jan → Jun 2026 overdue | chronic pain syndrome | The Affiliated Hospital of Qingdao University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RFUS-949 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07676357 ↗ |
| Route | Oral | “Participants receive RFUS-949 100 mg tablets orally once daily (QD) for 6 consecutive days” NCT07676357 ↗ |